EMCDDA. New drugs in Europe, 2013, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2014. 311 kB.
Hess, C; Murach, J; Krueger, L; Scharrenbroch, L; Unger, M; Madea, B; Sydow, K. Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples Drug Test. Anal., 1 May 2017, 9 (5), 721-733. 267 kB. https://doi.org/10.1002/dta.2030 #5 fluoro SDB 006 LC,MS
Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report) Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #7. 5F-SDB-006
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: Evolution In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 191-226. 1.2 MB. https://doi.org/10.1007/164_2018_144 #37
Ametovski, A; Macdonald, C; Manning, JJ; Haneef, SAS; Santiago, M; Martin, L; Sparkes, E; Reckers, A; Gerona, RR; Connor, M; Glass, M; Banister, SD. Exploring stereochemical and conformational requirements at cannabinoid receptors for synthetic cannabinoids related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA ACS Chem. Neurosci., 4 Nov 2020, 11 (21), 3672–3682. 3.5 MB. https://doi.org/10.1021/acschemneuro.0c00591 #11 MS,NMR